Added to YB: 2026-05-15
Pitch date: 2026-05-13
HROW [neutral]
Harrow, Inc.
Author Info
MVC Investing is a long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation. Sign up for the newsletter.
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
32.65
P/E
-73.98
EV/Sales
4.90
Sector
Pharmaceuticals
Category
growth
Harrow (HROW): Q1 2026 Earnings Review
HROW (earnings): Q1 rev $44.2M vs $52.5M est (-8% YoY), adj EBITDA -$12.7M vs -$3.1M est, EPS -$0.74 vs -$0.37 est. ~$8M VEVYE gross-to-net hit from CVS coverage pricing issue (now resolved). Reiterated FY26 guide $350-365M rev, $80-100M EBITDA despite Q1 miss creates high H2 bar. VEVYE demand strong: NRx +25% QoQ, surpassed Xiidra share, ~30% ASP improvement expected. IHEEZO unit demand +18% YoY despite ASC headwind. July catalysts: BYOOVIZ launch, IOPIDINE J-code, BYQLOVI sampling. Thesis intact but guidance credibility damaged again.
Read full article (13 min)